A Phase 1/2 interventional study of VELCADE in Amyloidosis, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-25.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.
Among the 141 studies in Amyloidosis with a site in United States, this one is the 43rd largest by enrollment of the 99 interventional ones that give a count, is one of 3 that started in 2005, is one of 12 in phase 1/2, and was the 7th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
GlaxoSmithKline · Sites in United States, Australia, United Kingdom
Ages 18+
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Germany, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 46 · Phase 3 31 · Phase 4 3
First in 1979; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 45 across the 99 interventional studies, 107 across the 41 observational. Of the 84 that completed or were terminated, 44 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 141 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 3 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Amyloidosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05619302Phase 3Brigham and Women's HospitalMolecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis | 2026-12-31 |
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT06097832Nexcella Inc.Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | 2026-12 |
| NCT05951816University of Tennessee Graduate School of MedicineA Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis | 2026-12 |
| NCT07196839University of Texas Southwestern Medical CenterDetermining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 141 studies in Amyloidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VELCADE
Drug: VELCADE
Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2 Or Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2
Also known as: Bortezomib
Maximum Tolerated Dose
Maximum Tolerated Dose (MTD) was defined as the highest dose level that has 0/1 out of 6 patients experiences Dose Limited Toxicity (DLT). MTD is defined separately for QW and BIQ dose cohorts. DLT was defined as adverse events occurring during Cycle 1 and: (1) related to VELCADE, (2) Grade 4 thrombocytopenia or neutropenia, (3) Grade 3 or higher nonhematologic toxicity.
Time frame: 5 weeks in once weekly (QW) dose cohorts and 3 weeks in twice weekly (BIW) dose cohorts
Subjects With Treatment Emergent Adverse Events
Treatment emergent adverse events observed during outcome measure time frame
Time frame: from first study-related procedure to 30 days after last dose of study medication
Subjects With Serious Treatment Emergent Adverse Events
Serious treatment emergent adverse events observed during outcome measure time frame
Time frame: from first study-related procedure to 30 days after last dose of study medication
Subjects Grade 3/4/5 Treatment Emergent Adverse Events
Grade 3/4/5 treatment emergent adverse events observed during outcome measure time frame. Grade is determined according to Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0.
Time frame: from first study-related procedure to 30 days after last dose of study medication
Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination
Treatment emergent adverse events observed during outcome measure time frame leading to treatment termination
Time frame: from first study-related procedure to 30 days after last dose of study medication
Best Confirmed Hematologic Responders
Hematologic response was determined by the investigator per the response criteria for immunoglobulin light chain amyloidosis by Gertz (2005). It include Complete and Partial Responders (CR+PR). CR requires serum and urine negative for a monoclonal protein by immunofixation and free light chain ratio normal. PR requires: 1. reduction in quantitative serum M-protein by 50% if baseline value is at least 0.5 g/dL, 2. if light chain is detected in the urine (with a consistent peak and \>100 mg/ 24 hours), then 50% reduction is required, 3. if free light chain \>10 mg/dL, reduction by 50% is required.
Time frame: from first dose of study medication to end of study visit
| Milestone | Single Agent VELCADE |
|---|---|
| Started | 70 |
| Completed | 24 |
| Not completed | 46 |
| Withdrew: Adverse event | 18 |
| Withdrew: Death | 2 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Treatment ongoing | 4 |
| Withdrew: Progression of amyloid markers | 4 |
| Withdrew: Deterioration in kps and organ function | 1 |
| Withdrew: Subjects overall condition deterioration | 4 |
| Withdrew: Other | 4 |
Maximum Tolerated Dose (MTD) was defined as the highest dose level that has 0/1 out of 6 patients experiences Dose Limited Toxicity (DLT). MTD is defined separately for QW and BIQ dose cohorts. DLT was defined as adverse events occurring during Cycle 1 and: (1) related to VELCADE, (2) Grade 4 thrombocytopenia or neutropenia, (3) Grade 3 or higher nonhematologic toxicity.
| participants with DLT | Single Agent VELCADE |
|---|---|
| Maximum Tolerated Dose | 2 |
Treatment emergent adverse events observed during outcome measure time frame
| participants | Single Agent VELCADE |
|---|---|
| Subjects With Treatment Emergent Adverse Events | 70 |
Hematologic response was determined by the investigator per the response criteria for immunoglobulin light chain amyloidosis by Gertz (2005). It include Complete and Partial Responders (CR+PR). CR requires serum and urine negative for a monoclonal protein by immunofixation and free light chain ratio normal. PR requires: 1. reduction in quantitative serum M-protein by 50% if baseline value is at least 0.5 g/dL, 2. if light chain is detected in the urine (with a consistent peak and \>100 mg/ 24 hours), then 50% reduction is required, 3. if free light chain \>10 mg/dL, reduction by 50% is required.
| participants responded | Single Agent VELCADE |
|---|---|
| Best Confirmed Hematologic Responders | 33 |
Serious treatment emergent adverse events observed during outcome measure time frame
| participants | Single Agent VELCADE |
|---|---|
| Subjects With Serious Treatment Emergent Adverse Events | 25 |
Grade 3/4/5 treatment emergent adverse events observed during outcome measure time frame. Grade is determined according to Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0.
| participants | Single Agent VELCADE |
|---|---|
| Subjects Grade 3/4/5 Treatment Emergent Adverse Events | 43 |
Treatment emergent adverse events observed during outcome measure time frame leading to treatment termination
| participants | Single Agent VELCADE |
|---|---|
| Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination | 23 |
Collected over from first study-related procedure to 30 days after last dose of study medication. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Agent VELCADE | — | 25/70 (35.7%) | 70/70 (100%) |
| Event | Single Agent VELCADE |
|---|---|
| PneumoniaInfections and infestations | 3/70 |
| DiarrhoeaGastrointestinal disorders | 2/70 |
| VomitingGastrointestinal disorders | 2/70 |
| Renal failure acuteRenal and urinary disorders | 2/70 |
| HypotensionVascular disorders | 2/70 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/70 |
| Atrial fibrillationCardiac disorders | 1/70 |
| Cardiac failure acuteCardiac disorders | 1/70 |
| Cardiac failure cogestiveCardiac disorders | 1/70 |
| Restrictive cardiomyopathyCardiac disorders | 1/70 |
| Event | Single Agent VELCADE |
|---|---|
| DizzinessNervous system disorders | 21/70 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 19/70 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/70 |
| ParaesthesiaNervous system disorders | 17/70 |
| Oedema peripheralGeneral disorders | 16/70 |
| HeadacheNervous system disorders | 16/70 |
| OedemaGeneral disorders | 15/70 |
| Back painMusculoskeletal and connective tissue disorders | 13/70 |
| Abdominal distensionGastrointestinal disorders | 12/70 |
| PyrexiaGeneral disorders | 12/70 |
| Age, Categorical(Participants) | Single Agent VELCADE |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 43 |
| >=65 years | 27 |
| Age Continuous(years) | Single Agent VELCADE |
|---|---|
| Mean | 61 ± 10.10 |
| Sex: Female, Male(Participants) | Single Agent VELCADE |
|---|---|
| Female | 31 |
| Male | 39 |
| Region of Enrollment(participants) | Single Agent VELCADE |
|---|---|
| United States | 35 |
| Canada | 8 |
| France | 3 |
| Germany | 11 |
| Italy | 9 |
| Spain | 4 |
The record gives a start of Jun 2005, a primary completion of Jul 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib
Millennium Pharmaceuticals, Inc. →